Back to results

CompletedPhase 2

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

NCT00266240

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Tucson, Arizona, United States

+43 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2005-11
Enrollment: 267 participants
Sponsor: Hoffmann-La Roche
Purpose: treatment

Locations (44)

Tucson, Arizona, United States
Pine Bluff, Arkansas, United States
Chula Vista, California, United States
Spring Valley, California, United States
West Hills, California, United States
Hollywood, Florida, United States
Atlanta, Georgia, United States
Binghamton, New York, United States
Fayetteville, North Carolina, United States
Statesville, North Carolina, United States
Winston-Salem, North Carolina, United States
Springdale, Ohio, United States
Oklahoma City, Oklahoma, United States
Medford, Oregon, United States
Beaver, Pennsylvania, United States
Tipton, Pennsylvania, United States
Mt. Pleasant, South Carolina, United States
Plano, Texas, United States
Renton, Washington, United States
Dimitrovgrad, Bulgaria
Pleven, Bulgaria
Rousse, Bulgaria
Sofia, Bulgaria
Sofia, Bulgaria
Sofia, Bulgaria
Sofia, Bulgaria
Zagreb, Croatia
Guatemala City, Guatemala
Budapest, Hungary
Budapest, Hungary
Győr, Hungary
Kecskemét, Hungary
Chihuahua City, Mexico
Cuernavaca, Mexico
Durango, Mexico
Mexico City, Mexico
Mexico City, Mexico
Mexico City, Mexico
Mexico City, Mexico
Bialystok, Poland
Gdansk, Poland
Gorzów, Poland
Krakow, Poland
Wroclaw, Poland

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus — TrialFind